| Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014 | 1827 | 2014 |
| A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 RJ Hung, JD McKay, V Gaborieau, P Boffetta, M Hashibe, D Zaridze, ... Nature 452 (7187), 633-637, 2008 | 1480 | 2008 |
| Probability of cancer in pulmonary nodules detected on first screening CT A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ... New England journal of medicine 369 (10), 910-919, 2013 | 1300 | 2013 |
| Patient preferences for oral versus intravenous palliative chemotherapy. G Liu, E Franssen, MI Fitch, E Warner Journal of Clinical Oncology 15 (1), 110-115, 1997 | 1168 | 1997 |
| First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ... New England Journal of Medicine 383 (21), 2018-2029, 2020 | 735 | 2020 |
| Sensitive tumour detection and classification using plasma cell-free DNA methylomes SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ... Nature 563 (7732), 579-583, 2018 | 701 | 2018 |
| Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open … AT Shaw, TM Kim, L Crinò, C Gridelli, K Kiura, G Liu, S Novello, A Bearz, ... The Lancet Oncology 18 (7), 874-886, 2017 | 566 | 2017 |
| Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ... Nature genetics 49 (7), 1126-1132, 2017 | 515 | 2017 |
| Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... The lancet oncology 17 (4), 452-463, 2016 | 503 | 2016 |
| Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer Y Wang, JD McKay, T Rafnar, Z Wang, MN Timofeeva, P Broderick, ... Nature genetics 46 (7), 736-741, 2014 | 429 | 2014 |
| XPD and XRCC1 Genetic Polymorphisms Are Prognostic Factors in Advanced Non—Small-Cell Lung Cancer Patients Treated With Platinum Chemotherapy S Gurubhagavatula, G Liu, S Park, W Zhou, L Su, JC Wain, TJ Lynch, ... Journal of Clinical Oncology 22 (13), 2594-2601, 2004 | 426 | 2004 |
| Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy W Zhou, S Gurubhagavatula, G Liu, S Park, DS Neuberg, JC Wain, ... Clinical Cancer Research 10 (15), 4939-4943, 2004 | 395 | 2004 |
| Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review EL Stewart, SZ Tan, G Liu, MS Tsao Translational lung cancer research 4 (1), 67, 2015 | 372 | 2015 |
| Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma HI Pass, SM Levin, MR Harbut, J Melamed, L Chiriboga, J Donington, ... New England Journal of Medicine 367 (15), 1417-1427, 2012 | 325 | 2012 |
| Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations G Lal, G Liu, B Schmocker, P Kaurah, H Ozcelik, SA Narod, M Redston, ... Cancer research 60 (2), 409-416, 2000 | 292 | 2000 |
| Polymorphisms in the DNA Repair Genes XRCC1 and ERCC2, Smoking, and Lung Cancer Risk W Zhou, G Liu, DP Miller, SW Thurston, LL Xu, JC Wain, TJ Lynch, L Su, ... Cancer Epidemiology Biomarkers & Prevention 12 (4), 359-365, 2003 | 280 | 2003 |
| Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium DR Brenner, P Boffetta, EJ Duell, H Bickeboeller, A Rosenberger, ... American journal of epidemiology 176 (7), 573-585, 2012 | 263 | 2012 |
| Circulating 25-hydroxyvitamin D levels predict survival in early-stage non–small-cell lung cancer patients W Zhou, RS Heist, G Liu, K Asomaning, DS Neuberg, BW Hollis, JC Wain, ... Journal of Clinical Oncology 25 (5), 479-485, 2007 | 245 | 2007 |
| Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of … T John, G Liu, MS Tsao Oncogene 28 (1), S14-S23, 2009 | 241 | 2009 |
| Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer C Lim, MS Tsao, LW Le, FA Shepherd, R Feld, RL Burkes, G Liu, ... Annals of Oncology 26 (7), 1415-1421, 2015 | 223 | 2015 |
Natasha LeighlMedical Oncology, Princess MargaretVerified email at uhn.ca
